Joint imaging platform for federated clinical data analytics

J Scherer, M Nolden, J Kleesiek, J Metzger… - JCO clinical cancer …, 2020 - ascopubs.org
PURPOSE Image analysis is one of the most promising applications of artificial intelligence
(AI) in health care, potentially improving prediction, diagnosis, and treatment of diseases …

6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival

R García‐Sanz, I Dogliotti, GM Zaccaria… - British Journal of …, 2021 - Wiley Online Library
Deletion of the long arm of chromosome 6 (del6q) is the most frequent cytogenetic
abnormality in Waldenström macroglobulinaemia (WM), occurring in approximately 50% of …

Development and validation of a simplified score to predict early relapse in newly diagnosed multiple myeloma in a pooled dataset of 2,190 patients

GM Zaccaria, L Bertamini, MT Petrucci, M Offidani… - Clinical Cancer …, 2021 - AACR
Purpose: Despite the improvement of therapeutic regimens, several patients with multiple
myeloma (MM) still experience early relapse (ER). This subset of patients currently …

A clinical prognostic model based on machine learning from the Fondazione Italiana Linfomi (FIL) MCL0208 phase III trial

GM Zaccaria, S Ferrero, E Hoster, R Passera… - Cancers, 2021 - mdpi.com
Simple Summary The interest in using Machine-Learning (ML) techniques in clinical
research is growing. We applied ML to build up a novel prognostic model from patients …

Electronic case report forms generation from pathology reports by ARGO, automatic record generator for onco-hematology

GM Zaccaria, V Colella, S Colucci, F Clemente… - Scientific Reports, 2021 - nature.com
The unstructured nature of Real-World (RW) data from onco-hematological patients and the
scarce accessibility to integrated systems restrain the use of RW information for research …

Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial

S Ferrero, D Grimaldi, E Arrigoni, M Pironti… - Blood …, 2023 - ashpublications.org
Abstract In the Fondazione Italiana Linfomi MCL0208 phase 3 trial, lenalidomide
maintenance (LEN) after autologous stem cell transplantation (ASCT) in mantle cell …

[HTML][HTML] Minimal residual disease (MRD) in mantle cell lymphoma

M Ladetto, R Tavarozzi, C Pott - Annals of Lymphoma, 2020 - aol.amegroups.org
Mantle cell lymphoma (MCL) is a rare, aggressive non-Hodgkin lymphoma (NHL)
characterized by considerable biological and clinical heterogeneity. A number of baseline …

[PDF][PDF] Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial

NCF ABCB - 2023 - arpi.unipi.it
Mantle cell lymphoma (MCL) is an aggressive, mature B-cell non-Hodgkin lymphoma
historically known for its poor long-term outcome. 1 In recent years, the introduction of novel …

[PDF][PDF] LENALIDOMIDE VS OSSERVAZIONE NEL LINFOMA MANTELLARE: RISULTATI CLINICI E MOLECOLARI A LUNGO TERMINE DI UNO STUDIO DI FASE III

A MAZZOCATO - 2023 - unitesi.uniupo.it
Lo studio di fase III FIL MCL0208 ha confrontato l'utilizzo di LEN per due anni con
l'osservazione (OBS) dopo il trapianto autologo di cellule staminali (ASCT) in giovani (< 65 …